These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 28692916)

  • 1. Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.
    Chen W; Guo N; Qi M; Dai H; Hong M; Guan L; Huan X; Song S; He J; Wang Y; Xi Y; Yang X; Shen Y; Su Y; Sun Y; Gao Y; Chen Y; Ding J; Tang Y; Ren G; Miao Z; Li J
    Eur J Med Chem; 2017 Sep; 138():514-531. PubMed ID: 28692916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy.
    Chen WH; Song SS; Qi MH; Huan XJ; Wang YQ; Jiang H; Ding J; Ren GB; Miao ZH; Li J
    Acta Pharmacol Sin; 2017 Nov; 38(11):1521-1532. PubMed ID: 28770827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent.
    Wang B; Chu D; Feng Y; Shen Y; Aoyagi-Scharber M; Post LE
    J Med Chem; 2016 Jan; 59(1):335-57. PubMed ID: 26652717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, preliminarily biological evaluation and molecular docking study of new Olaparib analogues as multifunctional PARP-1 and cholinesterase inhibitors.
    Gao CZ; Dong W; Cui ZW; Yuan Q; Hu XM; Wu QM; Han X; Xu Y; Min ZL
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):150-162. PubMed ID: 30427217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High affinity and low PARP-trapping benzimidazole derivatives as a potential warhead for PARP1 degraders.
    Peng X; Li Y; Qu J; Jiang L; Wu K; Liu D; Chen Y; Peng J; Guo Y; Cao X
    Eur J Med Chem; 2024 May; 271():116405. PubMed ID: 38678823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of novel synthesized phthalazinone-based PARP-1 inhibitors with apoptosis inducing mechanism in lung cancer.
    Almahli H; Hadchity E; Jaballah MY; Daher R; Ghabbour HA; Kabil MM; Al-Shakliah NS; Eldehna WM
    Bioorg Chem; 2018 Apr; 77():443-456. PubMed ID: 29453076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
    Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
    Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer.
    Mazzucchelli S; Truffi M; Baccarini F; Beretta M; Sorrentino L; Bellini M; Rizzuto MA; Ottria R; Ravelli A; Ciuffreda P; Prosperi D; Corsi F
    Sci Rep; 2017 Aug; 7(1):7505. PubMed ID: 28790402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of some barbituric and 1,3-dimethylbarbituric acid derivatives: A non-classical scaffold for potential PARP1 inhibitors.
    Eldin A Osman E; Hanafy NS; George RF; El-Moghazy SM
    Bioorg Chem; 2020 Nov; 104():104198. PubMed ID: 32920355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer.
    Fu L; Wang S; Wang X; Wang P; Zheng Y; Yao D; Guo M; Zhang L; Ouyang L
    Sci Rep; 2016 Dec; 6(1):3. PubMed ID: 28442756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, Synthesis and Activity Evaluation of New Phthalazinone PARP Inhibitors.
    Huang M; Ren J; Wang Y; Chen X; Yang J; Tang T; Yang Z; Li X; Ji M; Cai J
    Chem Pharm Bull (Tokyo); 2021; 69(7):620-629. PubMed ID: 34193711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of apoptosis in MDA-MB-231 breast cancer cells by a PARP1-targeting PROTAC small molecule.
    Zhao Q; Lan T; Su S; Rao Y
    Chem Commun (Camb); 2019 Jan; 55(3):369-372. PubMed ID: 30540295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, biological evaluation of novel piperidine-based derivatives as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.
    Lin C; Liu C; Hu P; Zou Z; Sun G
    Bioorg Chem; 2024 Jul; 148():107455. PubMed ID: 38772289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of novel phthalazinone derivatives as potent poly(ADP-ribose)polymerase 1 inhibitors.
    Xin M; Sun J; Huang W; Tang F; Liu Z; Jin Q; Wang J
    Future Med Chem; 2020 Oct; 12(19):1691-1707. PubMed ID: 33012191
    [No Abstract]   [Full Text] [Related]  

  • 16. Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.
    Yuan Z; Chen S; Sun Q; Wang N; Li D; Miao S; Gao C; Chen Y; Tan C; Jiang Y
    Bioorg Med Chem; 2017 Aug; 25(15):4100-4109. PubMed ID: 28601509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors.
    Chen X; Huan X; Liu Q; Wang Y; He Q; Tan C; Chen Y; Ding J; Xu Y; Miao Z; Yang C
    Eur J Med Chem; 2018 Feb; 145():389-403. PubMed ID: 29335205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of novel dual target inhibitors of PARP and HSP90 and their antitumor activities.
    Lin S; Zhang L; Zhang X; Yu Z; Huang X; Xu J; Liu Y; Chen L; Wu L
    Bioorg Med Chem; 2020 May; 28(9):115434. PubMed ID: 32222339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and biological evaluation of novel chrysin derivatives as poly(ADP-ribose) polymerase 1 (PARP1) inhibitors for the treatment of breast cancer.
    Yang Y; Tong J; Xie X; Cao H; Fu Y; Luo Y; Liu S; Chen W; Yang N
    Chin J Nat Med; 2024 May; 22(5):455-465. PubMed ID: 38796218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials.
    Wang L; Yang C; Xie C; Jiang J; Gao M; Fu L; Li Y; Bao X; Fu H; Lou L
    Cancer Sci; 2019 Mar; 110(3):1064-1075. PubMed ID: 30663191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.